Essence controls in pharmaceutical enterprise systems

Naveen Rajora *

Master’s in Business Administration, Bachelor of Science, Cognizant Technology Solutions, New Jersey, USA.
 
Review
International Journal of Science and Research Archive, 2023, 08(02), 012–017.
Article DOI: 10.30574/ijsra.2023.8.2.0197
Publication history: 
Received on 14 January 2023; revised on 27 February 2023; accepted on 01 March 2023
 
Abstract: 
The healthcare access is fundamental rights for every human being. It is Government’s responsibility to provide authentic Medicines and good healthcare system to its people as essential part of human life. Currently many governments across the countries are coming up with many welfare schemes to provide good healthcare services as a fundamental right. Pharmaceutical industry is also considered an essential part of healthcare services as it continuously invents new drugs to improve people’s life. 
New research and their potential outcomes raising new hopes of curing critical and rare diseases.  Pharmaceutical industry must adopt innovative technologies in enterprise systems which help to control the process of medicine invention from research stage to final drug approval. Enterprise system secure the research information and patients confidential data, maintain Good manufacturing Practice (GMP) in production to manufacture breakthrough medicine for improving human life expectancy and quality of life. Enterprise system also provide accurate information’s for internal and external audit. Enterprise system in pharmaceutical business process effectively reduce defects and Corrective and Preventive Actions (CAPA). New drug development and alternatives of expensive medicines are offering cost effective and affordable treatment plans to poor population. However, adopting new technologies in enterprise systems and improving existing infrastructure is another key challenge for poor and developing countries [1]. The complex and lengthy process of drug launch and huge investment on research and development make process more vulnerable when results are discovered without any prominent health improvements [2]. Newly launch drugs are trend to be costly and unaffordable for poor patients who need them and put a high pressure on health care budgets. These trends raise questions about incentives at work in the pharmaceutical sector and the sustainability of current pricing models. 
 
Keywords: 
Key controls of Pharmaceuticals; Enterprise Systems; Regulatory compliance; Pharmaceutical Barcode; Pharmaceutical Serialization; Drug price controls; Master Data Governance
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0